HALIFAX, June 23, 2011 /CNW/ - Immunovaccine Inc. (TSX-V: IMV) (the
"Company" or "Immunovaccine"), a clinical stage vaccine developer,
today announced the results of the Company's annual general meeting of
shareholders (AGM) held on June 22, 2011.
At the AGM, the shareholders elected Brad Thompson, Ph.D., and Kimberly
Stephens, C.A., as new directors and re-elected: Dr. William A.
Cochrane, Wade K. Dawe, James W. Hall and Albert Scardino to serve on
the Board of Directors until the next annual meeting of shareholders.
Albert Scardino will also assume the duties of the non-executive Chair
of the Board. Former directors Michael Kirby and Paul Kirkconnell did
not stand for re-election.
"The Board and management wish to thank Mr. Kirby and Mr. Kirkconnell
for their service and contributions to the Board," said Albert
Scardino, Chair of Immunovaccine.
The shareholders approved all motions put forth at the meeting including
the appointment of PricewaterhouseCoopers LLP, Chartered Accountants,
as the Company's independent auditors.
Immunovaccine Inc. is focused on the commercialization of its patented
DepoVax™ vaccine delivery platform and product candidates. Currently,
the Company has developed two therapeutic cancer vaccine candidates for
clinical trials. With the goal of developing premium therapeutic cancer
and infectious disease vaccines, Immunovaccine continues to strengthen
its vaccine pipeline through licensing and strategic partnerships with
companies worldwide. www.imvaccine.com
This press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. However,
they should not be regarded as a representation that any of the plans
will be achieved. Actual results may differ materially from those set
forth in this press release due to risks affecting the Company,
including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc.
assumes no responsibility to update forward-looking statements in this
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Immunovaccine Inc.
For further information:
Kimberly Stephens, C.A., CFO, Immunovaccine Inc.
T: (902) 492-1819 E: firstname.lastname@example.org
Jennifer Ayotte, Director Communications, Immunovaccine Inc.
T: (902) 492-1819 E: email@example.com